{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hyperthyroidism/management/pre-conception-pregnancy-postpartum/","result":{"pageContext":{"chapter":{"id":"f01fb4b1-5479-506a-aab6-3d89022ca8d1","slug":"pre-conception-pregnancy-postpartum","fullItemName":"Scenario: Pre-conception, pregnancy, and postpartum","depth":2,"htmlHeader":"<!-- begin field 73339944-b60f-455e-a767-9e512fa552d9 --><h2>Scenario: Pre-conception, pregnancy, and postpartum</h2><!-- end field 73339944-b60f-455e-a767-9e512fa552d9 -->","summary":"Covers the management of pre-conception, pregnant, or postpartum women with hyperthyroidism.","htmlStringContent":"<!-- begin item c4b94837-2dd1-49df-813c-db4468ed58e8 --><!-- begin field a05a9df4-354a-4749-84b9-acbc0159e9b9 --><p>From age 18 years onwards (Female).</p><!-- end field a05a9df4-354a-4749-84b9-acbc0159e9b9 --><!-- end item c4b94837-2dd1-49df-813c-db4468ed58e8 -->","topic":{"id":"c3c8bd52-950a-5ac1-a8f6-31ee314de753","topicId":"4369594d-9952-48d2-89e3-17e591c8762d","topicName":"Hyperthyroidism","slug":"hyperthyroidism","lastRevised":"Last revised in January 2021","chapters":[{"id":"59f9bdf8-6311-583d-9fe9-52c678d352db","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"146e5bec-d1eb-5ba0-9e81-f3816c76c97a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"129b45b2-8296-54fd-9b82-246f53a0c38a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"94bb9adc-590a-5092-a39d-eafdcb359b5b","slug":"changes","fullItemName":"Changes"},{"id":"0587f71f-c66c-57d3-82dc-d217875883ba","slug":"update","fullItemName":"Update"}]},{"id":"1056d2a8-5a53-5386-8dab-1f19fc4a963f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d5707303-4d8e-53dd-9591-510f1f75ea88","slug":"goals","fullItemName":"Goals"},{"id":"c725a50c-0e88-5dca-a743-83b0aec2cf6e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"423f188d-b3d1-599b-b36e-d8986253ac12","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a7f71a23-ba29-5115-a37a-e10730ecfebe","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3769fad6-d54a-5b84-9378-d5fed321c43f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f546d633-22ad-5b3a-addf-c14ed5a316e4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a47d1c6f-bb45-556c-9f6f-1be5eb0fee97","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"87205244-f824-5403-8c75-27a9396c3d3c","slug":"definition","fullItemName":"Definition"},{"id":"297effea-8b73-56d9-b953-894efa713b64","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"6c2d617f-c4bf-53cd-ad15-3c4e50b4f917","slug":"causes","fullItemName":"Causes"},{"id":"a8477f19-2c3c-55eb-9cf0-52683adbf104","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5d8a6eb0-ae1c-5dc0-976b-c6dc76c822d0","slug":"complications","fullItemName":"Complications"},{"id":"606c2ced-041a-59db-84ad-9bdbc9d30b29","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"25bebca1-01a3-571a-bc2f-de52655661fd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"535b7a8d-3411-51df-831d-85332e2925e0","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"3e2f3be8-a4e7-55cc-a90e-fc9bc179ce65","slug":"assessment","fullItemName":"Assessment"}]},{"id":"c4bec08d-e5b3-509c-bea9-a31e8270f443","fullItemName":"Management","slug":"management","subChapters":[{"id":"4b553103-7c9a-5df2-a66d-ca71eb230d75","slug":"management","fullItemName":"Scenario: Management"},{"id":"f01fb4b1-5479-506a-aab6-3d89022ca8d1","slug":"pre-conception-pregnancy-postpartum","fullItemName":"Scenario: Pre-conception, pregnancy, and postpartum"}]},{"id":"410c1a25-4e25-5a82-9e68-74da126c2a52","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8a4baacf-8743-54dd-b0d2-6f9c63faed0f","slug":"propylthiouracil","fullItemName":"Propylthiouracil"},{"id":"5fecf90d-1aa4-5bb3-9e03-3603d3bff170","slug":"carbimazole","fullItemName":"Carbimazole"},{"id":"9f0433e8-fb86-5755-b708-070c08e61a4e","slug":"beta-blockers","fullItemName":"Beta-blockers"}]},{"id":"d5890c99-4277-5691-82b8-db4d899a0577","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"02257fcd-f37e-5344-be29-947639722e86","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ad43c9e6-b7b5-5112-a0c3-cceb0846f218","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"19745d5f-1ede-5a4c-bc7f-14ffd9dcb077","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"28c4e1a4-4c14-58af-a7eb-7064465157f4","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"afef01bd-ae56-54fa-96f9-395242020ab0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1fc2600e-afe1-582b-b40e-ba61a21de9f7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b29c805a-fe2a-529d-a4e8-e0a837f7663c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c4bec08d-e5b3-509c-bea9-a31e8270f443","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"51bce94a-4b05-558e-be1f-7eaa64ef6336","slug":"managing-women-pre-conception","fullItemName":"Managing women pre-conception","depth":3,"htmlHeader":"<!-- begin field 8e15fc62-ab5e-4295-b81b-3e400dc9d6fe --><h3>How should I manage a woman who is planning a pregnancy?</h3><!-- end field 8e15fc62-ab5e-4295-b81b-3e400dc9d6fe -->","summary":null,"htmlStringContent":"<!-- begin item 3453da04-b102-474c-849a-4cc406c3aac1 --><!-- begin field c0419eb4-f4d1-4fb2-b769-9bdd1c7b23b1 --><ul><li><strong>Arrange referral to an endocrinology specialist for all women with overt or subclinical hyperthyroidism</strong> who are planning a pregnancy, for pre-pregnancy counselling.<ul><li>Check serum thyroid-stimulating hormone (TSH) and free thyroxine (FT4) levels, and consider checking thyroid peroxidase antibody (TPOAb) status before conception.</li><li>Advise any woman with untreated hyperthyroidism to delay conception and use contraception until she has had specialist assessment and thyroid function has normalized. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a> for more information. </li></ul></li><li><strong>Advise the woman to seek immediate medical advice</strong> if pregnancy is suspected or confirmed.</li><li><strong>If a woman has had recent <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/management/management/#specialist-investigations-management\">radioactive iodine treatment</a>,</strong> advise her to avoid becoming pregnant for at least six months after treatment.</li><li><strong>Offer advice on sources of information and support,</strong> such as:<ul><li>The British Thyroid Foundation leaflet <a data-hyperlink-id=\"2d5bfb87-7809-4d71-af64-ab500099dba0\" href=\"https://www.btf-thyroid.org/Handlers/Download.ashx?IDMF=941f817e-a8da-4ea9-8ee9-83772477c280\" target=\"_blank\">Your guide to pregnancy and fertility in thyroid disorders</a> may be helpful.</li></ul></li></ul><!-- end field c0419eb4-f4d1-4fb2-b769-9bdd1c7b23b1 --><!-- end item 3453da04-b102-474c-849a-4cc406c3aac1 -->","subChapters":[{"id":"2deb0ff0-10df-508e-a9fe-e1585edfe68d","slug":"basis-for-recommendation-499","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 34bf62eb-7e08-415f-bcd5-df211a48aa10 --><h4>Basis for recommendation</h4><!-- end field 34bf62eb-7e08-415f-bcd5-df211a48aa10 -->","summary":null,"htmlStringContent":"<!-- begin item 499418b8-7b48-4c23-a7f9-e4b54982e150 --><!-- begin field 0b8a6913-c5fe-4da0-b2af-748d6b363a03 --><p>The recommendations on the management of women planning a pregnancy are largely based on the National Institute of Health and Care Excellence (NICE) clinical guideline <em>Thyroid disease: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>], the UK joint publication <em>UK guidelines for the use of thyroid function tests</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">BTA et al, 2006</a>], the European Thyroid Association (ETA) publication <em>Guideline for the management of Graves' hyperthyroidism</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>], the Endocrine Society clinical practice guideline <em>Management of thyroid dysfunction during pregnancy and postpartum</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>], the American Thyroid Association (ATA) publications <em>Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>] and <em>Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>]; a Medicines and Healthcare products Regulatory Agency (MHRA) drug safety update <em>Carbimazole: increased risk of congenital malformations; strengthened advice on contraception</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">MHRA, 2019b</a>], and expert opinion in review articles on hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Vaidya and Pearse, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</p><h5>Arranging referral to an endocrinologist for pre-pregnancy counselling</h5><ul><li>The ETA publication on Graves' hyperthyroidism notes that women with Graves' disease of reproductive age should be offered pre-conception counselling and be stably euthyroid before attempting pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>].</li><li>The ATA guidelines on pregnancy advise that pregnancy should be postponed until a woman reaches a stable euthyroid state, and strongly recommend use of contraception until disease is controlled. In addition, women with Graves' disease should be counselled about the risks and benefits of treatment options and the woman's desired timeline to conception [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>]. The NICE clinical guideline recommends drug treatment with propylthiouracil for women trying to become pregnant within the next six months, who require treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>]. The ETA publication on Graves' hyperthyroidism recommends women with Graves' disease needing antithyroid drug treatment should be switched to propylthiouracil when planning pregnancy and during the first trimester [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>].</li><li>The Endocrine Society clinical practice guideline supports this approach, highlighting that in women with overt hyperthyroidism due to Graves' disease, antithyroid drug therapy should be started before pregnancy, if possible, or adjusted to achieve stability in thyroid function. Propylthiouracil is recommended in the first trimester in place of carbimazole, as the latter drug may be associated with an increased risk of congenital malformations [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>]. This is supported by an MHRA drug safety update which highlights the need for effective contraception for women of childbearing potential during treatment with carbimazole [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">MHRA, 2019b</a>].</li><li>The UK joint publication notes that women taking antithyroid drugs need specialist endocrinology review as alteration to the dose and drug may be needed if the woman becomes pregnant, to reduce the potential risk of fetal goitre and hypothyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">BTA et al, 2006</a>].</li><li>The recommendation to consider checking thyroid peroxidase antibody (TPO) status pre-conception is based on the fact that women with a positive result are at increased risk for obstetric complications including miscarriage, pre-term delivery, and postpartum thyroiditis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>].</li><li>The recommendation to refer all women with current or pre-existing subclinical hyperthyroidism to an endocrinologist is based on the expert opinion of previous external reviewers of this CKS topic, as further specialist investigations may be needed. CKS notes that the Endocrine Society clinical practice guideline found no evidence that treatment of subclinical hyperthyroidism improves pregnancy outcomes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>].</li></ul><h5>Seeking immediate medical advice if pregnancy is suspected or confirmed</h5><ul><li>This recommendation is extrapolated from advice for women with Graves' disease in the ATA guidelines on pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>] and the ETA guideline on Graves' hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>].</li></ul><h5>Advice for women who have had recent radioactive iodine treatment</h5><ul><li>This recommendation is based on the potential risk of damage to the fetal thyroid following treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>].</li></ul><!-- end field 0b8a6913-c5fe-4da0-b2af-748d6b363a03 --><!-- end item 499418b8-7b48-4c23-a7f9-e4b54982e150 -->","subChapters":[]}]},{"id":"5311e78a-b134-5122-bfe2-4038efcf228d","slug":"managing-pregnant-women","fullItemName":"Managing pregnant women","depth":3,"htmlHeader":"<!-- begin field cf77220e-ea18-439f-a950-bdb4be5a3bc4 --><h3>How should I manage a woman who is pregnant?</h3><!-- end field cf77220e-ea18-439f-a950-bdb4be5a3bc4 -->","summary":null,"htmlStringContent":"<!-- begin item dd9bc01b-b120-49ce-b262-029ec2c4aece --><!-- begin field 936c4b36-313c-4656-81dd-5a47542d75f7 --><ul><li><strong>Arrange emergency admission if the woman has a suspected serious complication</strong><strong> </strong>such as <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/background-information/complications/\">thyrotoxic crisis</a>, or intractable vomiting suggesting <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/background-information/causes/\">hyperemesis gravidarum</a>. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/\">Nausea/vomiting in pregnancy</a> for more information on hyperemesis gravidarum.</li><li><strong>Arrange urgent specialist referral for all other pregnant women</strong> with current or previous overt or subclinical hyperthyroidism, to a joint obstetric and endocrinology clinic, depending on local availability.<ul><li><div>Check serum thyroid-stimulating hormone (TSH), free thyroxine (FT4), and free triiodothyronine (FT3) levels for all women, and check serum TSH-receptor antibodies (TRAbs) if she has a current or previous history of Graves' disease, immediately once pregnancy is confirmed.</div><ul><li><div>Interpret the results using trimester-specific reference ranges and forward the results to the specialist team.</div></li></ul></li><li><div>If the woman is already taking <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/management/management/#specialist-investigations-management\">antithyroid drug treatment</a>, ensure blood monitoring is arranged and interpreted by the specialist team.</div></li></ul></li><li><strong>Seek urgent advice from an endocrinologist</strong> if:<ul><li>There is uncertainty whether current antithyroid drug treatment should be continued or changed during pregnancy.</li><li>The woman has troublesome adrenergic symptoms (such as palpitations, tremor, tachycardia, or anxiety) which require symptomatic treatment whilst awaiting specialist assessment.</li></ul></li><li><strong>Offer advice on sources of information and support,</strong> such as:<ul><li>The British Thyroid Foundation leaflet <a data-hyperlink-id=\"2f486624-d11b-4b39-b4e8-ab500099ef1a\" href=\"https://www.btf-thyroid.org/Handlers/Download.ashx?IDMF=941f817e-a8da-4ea9-8ee9-83772477c280\" target=\"_blank\">Your guide to pregnancy and fertility in thyroid disorders</a> may be helpful.</li></ul></li></ul><!-- end field 936c4b36-313c-4656-81dd-5a47542d75f7 --><!-- end item dd9bc01b-b120-49ce-b262-029ec2c4aece -->","subChapters":[{"id":"c39a47b6-b70a-5074-84d6-d9d0f1f6ee69","slug":"basis-for-recommendation-a9a","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 222cca52-4aad-405e-bfe0-a0934c6813a9 --><h4>Basis for recommendation</h4><!-- end field 222cca52-4aad-405e-bfe0-a0934c6813a9 -->","summary":null,"htmlStringContent":"<!-- begin item a9a8c4e1-7036-4bc6-8e8d-5ca0809c4aeb --><!-- begin field c46168b3-152d-43d3-9529-70932dfc657b --><p>The recommendations on the management of pregnant women with hyperthyroidism or subclinical hyperthyroidism are largely based on the National Institute of Health and Care Excellence (NICE) clinical guideline <em>Thyroid disease: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>], the UK joint publication <em>UK guidelines for the use of thyroid function tests</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">BTA et al, 2006</a>], the Endocrine Society clinical practice guideline <em>Management of thyroid dysfunction during pregnancy and postpartum</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>], the American Thyroid Association (ATA) publication <em>Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>], the European Thyroid Association (ETA) publication <em>Guideline for the management of Graves' hyperthyroidism</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>], and expert opinion in review articles on hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</p><h5>Arranging emergency admission if serious complication</h5><ul><li>This recommendation is based on the need for prompt and specialist treatment of potentially serious complications in pregnancy, to avoid significant maternal and fetal mortality and morbidity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">BTA et al, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>].</li></ul><h5>Arranging urgent referral for all other pregnant women</h5><ul><li>The recommendation to arrange specialist referral for all pregnant women is based on the fact that maternal hyperthyroidism is associated with maternal and fetal risks related to the disease itself and/or to its treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>].<ul><li>The ATA guidelines on pregnancy note that specialist assessment is needed to differentiate between Graves' hyperthyroidism and gestational transient thyrotoxicosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>].</li></ul></li><li>The recommendation that pregnant women with a history of hyperthyroidism who are currently euthyroid should also be referred for specialist assessment is based on the fact that previous successful treatment of hyperthyroidism does not guarantee the absence of thyroid-related problems during subsequent pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">BTA et al, 2006</a>].</li><li>Women treated with antithyroid drugs may need to have the drug or dose amended by a specialist when pregnancy is confirmed, as these drugs cross the placenta. Close monitoring of thyroid function and the need for antithyroid drug treatment during pregnancy is essential to minimize the risks of adverse fetal and maternal outcomes, including fetal overtreatment leading to fetal and neonatal hypothyroidism if the woman is taking excessive doses of antithyroid drugs during pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>].<ul><li>Propylthiouracil is used first-line in the first trimester of pregnancy in place of carbimazole, as the latter drug may be associated with an increased risk of congenital abnormalities in the first trimester. At the beginning of the second trimester, the woman should be switched back to carbimazole, as propylthiouracil has been associated with a small risk of severe liver damage [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li><li>During pregnancy, it is recommended that the dose of propylthiouracil and carbimazole is kept to the lowest possible needed to maintain euthyroidism, as these drugs cross the placenta and in high doses may cause fetal goitre and hypothyroidism. The latter may be associated with an increased risk of abnormal brain development, spontaneous miscarriage, and pre-term delivery [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">BTA et al, 2006</a>].</li><li>Expert opinion in a review article highlights the need for frequent thyroid function test (TFT) monitoring during pregnancy when taking antithyroid drugs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>].</li></ul></li><li>The recommendation to check thyroid-stimulating hormone (TSH) receptor antibodies (TRAb) levels during pregnancy in women with a current or previous history of Graves' disease is based on the fact it can help distinguish Graves' disease from gestational thyrotoxicosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>].<ul><li>TRAb is measurable in around 95% of people with active Graves' hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>].</li><li>The ETA guideline on Graves' hyperthyroidism recommends that all women with a history of autoimmune thyroid disease should have their TRAb levels measured at the first presentation of pregnancy, and notes that TRAbs are a useful predictive measure of fetal or neonatal hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>]. Similarly, expert opinion in a review article notes that a high maternal titre of TRAb can help to detect fetal thyrotoxicosis in pregnant women with Graves' disease, as these antibodies readily cross the placenta and stimulate the fetal thyroid [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>].</li><li>Conversely, women who are TRAb-negative and do not require antithyroid drug treatment during pregnancy have a very low risk of fetal or neonatal thyroid dysfunction [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>].</li></ul></li><li>The Endocrine Society clinical practice guideline notes there is no evidence that treatment of subclinical hyperthyroidism improves pregnancy outcomes, and treatment can potentially adversely affect fetal outcome [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>]. This approach is supported by expert opinion in a review article, which states that pregnant women with subclinical hyperthyroidism do not usually need treatment during pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>].</li><li>The recommendation to use trimester-specific reference ranges in pregnancy is based on the ATA guidelines on pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>].</li></ul><h5>Seeking urgent specialist advice</h5><ul><li>The recommendation to seek specialist advice regarding the appropriateness of antithyroid drug treatment during pregnancy is extrapolated from the Endocrine Society clinical practice guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>], the ATA guidelines on pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li><li>The recommendation to seek specialist advice if a pregnant woman has troublesome adrenergic symptoms is pragmatic, based on what CKS considers to be good clinical practice. In addition, long-term treatment with beta-blockers in pregnancy has been associated with intrauterine growth restriction, fetal bradycardia, and neonatal hypoglycaemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>].</li></ul><!-- end field c46168b3-152d-43d3-9529-70932dfc657b --><!-- end item a9a8c4e1-7036-4bc6-8e8d-5ca0809c4aeb -->","subChapters":[]}]},{"id":"5137b6d4-5ffe-5469-8257-4fe6d47bc7cd","slug":"managing-women-postpartum","fullItemName":"Managing women postpartum","depth":3,"htmlHeader":"<!-- begin field 1a104c14-47eb-4d81-a77a-bc1c2005c81e --><h3>How should I manage a woman who is postpartum?</h3><!-- end field 1a104c14-47eb-4d81-a77a-bc1c2005c81e -->","summary":null,"htmlStringContent":"<!-- begin item 3eada421-736f-4bf7-ac05-37087531bf28 --><!-- begin field 2c8c28d8-6106-4267-9635-019c711fe84c --><ul><li><strong>Ensure that all women with a diagnosis of overt or subclinical hyperthyroidism</strong><strong> have thyroid function tests (TFTs) checked after delivery.</strong> This should be arranged or co-ordinated by secondary care.<ul><li>If there is any uncertainty about the timing of TFTs, seek specialist advice.</li></ul></li><li><strong>Check serum thyroid-stimulating hormone (TSH) and free thyroxine (FT4) levels 6–8 weeks postpartum,</strong> particularly if the woman has any of the following:<ul><li>A goitre.</li><li>Symptoms suggestive of <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/background-information/causes/\">thyroiditis</a>.</li><li>A history of <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/background-information/causes/\">postpartum thyroiditis</a> or positive thyroid peroxidase antibodies (<a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/diagnosis/assessment/\">TPOAbs</a>).</li><li>A history of autoimmune thyroid disease, such as <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/background-information/causes/\">Graves&#39; disease</a>.</li></ul></li><li><strong>Arrange referral to an endocrinology specialist if the TFT results are abnormal, </strong>the urgency depending on clinical judgement.<ul><li>Be aware that women with postpartum thyroiditis may present with TFTs showing an initial thyrotoxic pattern.</li><li>Arrange TFT monitoring after resolution of the thyrotoxic phase, to screen for the hypothyroid phase, depending on specialist advice. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypothyroidism/\">Hypothyroidism</a> for more information on TFT monitoring in postpartum women.</li></ul></li><li><strong>Arrange annual monitoring of TFTs for all women with a history of postpartum thyroiditis which has resolved.</strong></li><li><div><strong>Offer advice on sources of information and support,</strong> such as:</div><ul><li><div>The British Thyroid Foundation leaflet <a data-hyperlink-id=\"d95c48c9-3483-46d6-b5a0-a98c00c69942\" href=\"http://www.btf-thyroid.org/information/leaflets/38-pregnancy-and-fertility-guide\">Your guide to pregnancy and fertility in thyroid disorders</a> may be helpful.</div></li></ul></li></ul><!-- end field 2c8c28d8-6106-4267-9635-019c711fe84c --><!-- end item 3eada421-736f-4bf7-ac05-37087531bf28 -->","subChapters":[{"id":"7fa3e36e-9c98-57c2-9034-d189a513265b","slug":"basis-for-recommendation-9fb","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field c3df3a10-f98b-404e-8ece-7ac510dbf9b2 --><h4>Basis for recommendation</h4><!-- end field c3df3a10-f98b-404e-8ece-7ac510dbf9b2 -->","summary":null,"htmlStringContent":"<!-- begin item 9fbce9b1-5324-4631-a431-b703c3bc1b02 --><!-- begin field ae9e5a55-cf16-4709-adbd-9025a7343d1e --><p>The recommendations on the management of postpartum women with hyperthyroidism or subclinical hyperthyroidism are based on the Endocrine Society clinical practice guideline <em>Management of thyroid dysfunction during pregnancy and postpartum</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>], the American Thyroid Association (ATA) publication <em>Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>], the European Thyroid Association (ETA) publication <em>Guideline for the management of Graves' hyperthyroidism</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>], the UK joint publication <em>UK guidelines on the use of thyroid function tests</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">BTA et al, 2006</a>], and expert opinion in a review article on hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>].</p><h5>Checking thyroid function tests (TFTs) 6–8 weeks postpartum</h5><ul><li>The UK joint publication notes that relapse of thyroid disease is more likely to occur after delivery, and Graves' disease may present <em>de novo</em> after delivery [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">BTA et al, 2006</a>].</li><li>The Endocrine Society clinical practice guideline notes that women at high risk of postpartum thyroiditis need screening of TFTs, including women with a history of postpartum thyroiditis and positive thyroid peroxidase antibodies (TPOAbs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>].<ul><li>The presence of TPOAbs in early pregnancy indicates a 40–60% risk of postpartum thyroiditis developing [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>].</li></ul></li><li>The ATA guidelines on pregnancy and the postpartum notes that women with positive TPOAbs are at increased risk of a more severe episode of postpartum thyroiditis, and are more likely to have a period of postpartum hypothyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>].</li></ul><h5>Arranging endocrinology referral if TFTs are abnormal</h5><ul><li>This recommendation is based on the fact that in women diagnosed with postpartum thyroiditis, if initial TFTs show a thyrotoxic pattern, specialist endocrinology tests such as a radioisotope uptake scan may be needed to differentiate postpartum thyroiditis from Graves' disease presenting <em>de novo</em> in the postpartum period [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">BTA et al, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>].<ul><li>Differentiation of the two conditions is important as each requires different treatments and have different clinical courses [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>].</li></ul></li><li>The ATA guidelines on pregnancy and the postpartum note that women with Graves' disease during pregnancy can have a relapse of disease, or may need increased antithyroid drug doses after pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>].</li><li>If a woman is breastfeeding, antithyroid drugs should be taken after breastfeeding in divided doses [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>].</li></ul><h5>Arranging annual TFT monitoring after resolution of postpartum thyroiditis</h5><ul><li>This recommendation is based on the fact that women with a history of postpartum thyroiditis are at increased risk of developing permanent primary hypothyroidism within 5–10 years of the episode of postpartum thyroiditis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">BTA et al, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Alexander, 2017</a>].</li></ul><!-- end field ae9e5a55-cf16-4709-adbd-9025a7343d1e --><!-- end item 9fbce9b1-5324-4631-a431-b703c3bc1b02 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}